Skip to main content
SpringerLink
Log in

Rapid isocratic HPLC investigation of radiochemical purity for 90Y-DOTATATE

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

DOTA-conjugated peptides, such as [DOTA0, Tyr3]ocreotide (DOTATOC) and [DOTA0, Tyr3]octreotate (DOTATATE) can be labeled with radionuclides such as 90Y, 177Lu and 111In at high specific activities. These radiolabelled somatostatin analogues are used for peptide receptor radionuclide therapy (PRRT). Currently, radio-high performance liquid chromatography (radio-HPLC) and radio-thin layer chromatography (radio-TLC) are the methods of choice for the analysis of the labeled compounds. In literature, radiochemical purity of the radiolabelled DOTATATE was investigated using gradient reversed-phase radio-HPLC. However, these studies indicate long retention time of the radiolabelled compound of 14.52 min. In our study, a new simple and rapid reversed-phase isocratic system enables the radiochemical purity of the radiolabelled DOTATATE within a few minutes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Krenning EP, Kwekkeboom DJ, Bakkar WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-ocreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731

    Article  CAS  Google Scholar 

  2. Otte A, Jermann E, Behe M et al (1997) DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med Mol Imaging 24:792–795

    CAS  Google Scholar 

  3. Krenning EP, Valkema R, Kooij PP et al (2000) The role of radioactive somatostatin and its analogues in the control of tumor growth. Rec Results Cancer Res 153:1–13

    CAS  Google Scholar 

  4. Breeman WA, De Jong M, Kwekkeboom DJ et al (2001) Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421–1429

    Article  CAS  Google Scholar 

  5. Breeman WA, De Jong M, Visser TJ et al (2003) Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30:917–920

    Article  CAS  Google Scholar 

  6. Wild D, Schmitt JS, Gini M et al (2003) DOTANOC, a high-affinity ligand of somatostatin receptors subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Nucl Med 30:1338–1347

    Article  CAS  Google Scholar 

  7. Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973

    Article  CAS  Google Scholar 

  8. De Jong M, Valkema R, Jamar F et al (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133–140

    Article  Google Scholar 

  9. Esser JP, Krenning EP, Teunissen JJ et al (2006) Comparison of [(177) Lu-OTA(0), Tyr(3)] octreotate and [(177) Lu-DOTA(0), Tyr(3)] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33:1346–1351

    Article  CAS  Google Scholar 

  10. Forrer F, Uusijarvi H, Waldherr C et al (2004) A comparison of (111) In-DOTATOC and (111) In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1257–1262

    Article  CAS  Google Scholar 

  11. Kwekkeboom D, Krenning EP, De Jong M (2000) Peptide receptor imaging and therapy. J Nucl Med 41:1704–1713

    CAS  Google Scholar 

  12. Erion J, Bugaj JE, Schmidt MA, Wilhelm RR, Srinivasan A (1999) High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-ocreotide in rat tumor model. 46th Annual meeting of the Society of Nuclear Medicine, Los Angeles, 6–10 June. Abstracts: J Nucl Med 40:223

  13. Kwekkeboom DJ, Bakker WH, Kooij PP et al (2001) [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients. Eur J Nucl Med 28:1319–1325

    Article  CAS  Google Scholar 

  14. Liu S, Cheung E, Ziegler MC et al (2001) (90) Y and (177) Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 12:559–568

    Article  CAS  Google Scholar 

  15. Pervez S, Mushtaq A (2005) Preparation, quality control and stability of 131I-Lanreotide. J Radioanal Nucl Chem 266(2):265–268

    Article  CAS  Google Scholar 

  16. Pandey U, Banarjee S, Mukherjee A, Sarma HD, Venkatesh M (2007) 90Y-DOTA-Lantreotide: a potential agent for targeted therapy. J Radioanal Nucl Chem 273(3):719–723

    Article  CAS  Google Scholar 

  17. Ishfaq MM, Hussain N, Jehangir M (2007) DOTA-Tyr3-Octreotate: labeling with β-emitting radionuclides for the preparation of potential therapeutic radiopharmaceuticals. J Radioanal Nucl Chem 273(3):689–694

    Article  CAS  Google Scholar 

  18. De Jong M, Bakker WH, Krenning EP et al (1997) Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0-D-Phe1-Tyr3]ocreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24:368–371

    Article  Google Scholar 

  19. Bakker WH, Krenning EP, Breeman WA et al (1991) In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism and binding to somatostatin receptor-positive tumors in man. J Nucl Med 32:1184–1189

    CAS  Google Scholar 

  20. Smith-Jones PM, Stolz B, Albert R et al (1998) Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumors. Nucl Med Biol 25:181–188

    Article  CAS  Google Scholar 

  21. Nardelli A, Castaldi E, Ortosecco G et al (2011) Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90. Appl Radiat Isot 69:52–55

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Çekmece Nuclear Research and Training Centre, Yarımburgaz Mah., Nükleer Araştırma Yolu, 34303, Istanbul, Turkey

    Betül Taşdelen, Aysun Ergun & Fikret Büyükkaya

Authors
  1. Betül Taşdelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aysun Ergun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fikret Büyükkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Betül Taşdelen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taşdelen, B., Ergun, A. & Büyükkaya, F. Rapid isocratic HPLC investigation of radiochemical purity for 90Y-DOTATATE. J Radioanal Nucl Chem 289, 573–575 (2011). https://doi.org/10.1007/s10967-011-1119-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-011-1119-6

Keywords

Search

Navigation